Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

G. Attard, J. Clark, L. Ambroisine, I. G. Mills, G. Fisher, P. Flohr, A. Reid, S. Edwards, G. Kovacs, D. Berney, C. Foster, C. E. Massie, A. Fletcher, J. S. De Bono, P. Scardino, J. Cuzick, C. S. Cooper

Research output: Contribution to journalArticlepeer-review

86 Citations (Scopus)

Abstract

A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5′-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5′-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

Original languageEnglish
Pages (from-to)314-320
Number of pages7
JournalBritish Journal of Cancer
Volume99
Issue number2
DOIs
Publication statusPublished - 1 Jul 2008

Keywords

  • ACSL3
  • ACSL3:ETV1 fusion
  • ETV1
  • Prostate cancer

Cite this